TMN10 Antibody
Description
Thymosin Beta-10 (TMSB10) Antibodies
Thymosin beta-10 (UniProt: P63313) is a 43-amino-acid protein regulating actin polymerization by sequestering G-actin monomers . Antibodies targeting TMSB10, such as ab14338 (Abcam) and AF6429 (R&D Systems), are polyclonal reagents validated for applications including ELISA and Western blot .
Key Features:
TMEM106B Antibodies
TMEM106B (UniProt: Q9NUM4) is a lysosomal transmembrane protein linked to neurodegenerative disorders. Antibodies targeting its C-terminal fragments (CTFs), such as residues 188–211 or 239–250, detect pathological aggregates in aging brains .
Thymosin Beta-10 Antibodies
TMEM106B Antibodies
A 2023 study validated six commercial TMEM106B antibodies :
| Antibody (RRID) | Clonality | Host | Validated Applications |
|---|---|---|---|
| ab244516 (AB_2924268) | Polyclonal | Rabbit | Immunofluorescence (IF) |
| 93334 (AB_2924267) | Recombinant | Rabbit | WB, IP, IF |
| PA5-63558 (AB_2648556) | Polyclonal | Rabbit | IF |
Key Findings:
-
Antibody 93334 (clone E7H7Z) demonstrated superior performance in Western blot and immunoprecipitation .
-
The polyclonal antibody targeting residues 188–211 showed strong affinity for TMEM106B CTFs in neurodegenerative brain tissues .
Thymosin Beta-10 in Cancer and Development
-
Overexpressed in gliomas and testicular carcinomas (detected via AF6429 in C6 and NTera-2 cell lines) .
-
Regulates tumor angiogenesis by blocking actin polymerization in endothelial cells .
TMEM106B in Neurodegeneration
-
CTF-specific antibodies (e.g., residues 188–211) identified pathological aggregates in 80% of frontotemporal dementia cases .
-
Immunohistochemical validation:
Technical Considerations for Antibody Use
Product Specs
Composition: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
Here’s a structured FAQ collection for researchers investigating T10B9 (MEDI-500), a monoclonal antibody referenced in the provided materials. The questions are categorized into basic and advanced tiers, with methodological guidance and evidence-based answers.
Advanced Research Questions
-
What methodologies identify γδ T-cell sparing effects and their functional implications?
Combine: -
How can conformational epitope mapping optimize T10B9’s specificity?
Adopt strategies from SFTSV Gn glycoprotein studies : -
What experimental designs address resistance to T10B9 in rejection therapy?
Leverage clinical observations of OKT3/T10B9 non-cross-reactivity :-
Develop in vitro HAMA neutralization assays with sequential antibody exposure
-
Test combinatorial regimens (e.g., T10B9 + CTLA-4-Ig) in mixed lymphocyte reaction (MLR) models
-
Comparative Analysis Table
| Parameter | T10B9 (MEDI-500) | OKT3 | Thymoglobulin |
|---|---|---|---|
| Target | TCRαβ heterodimer | CD3ε chain | Polyclonal (multiple) |
| Isotype | IgMκ | IgG2a | IgG (rabbit-derived) |
| γδ T-cell sparing | Yes | No | Partial |
| B-cell depletion | No | No | Yes |
| Depletion duration | 10–14 days | 7–10 days | >30 days |
| Cytokine release risk | Low | High | Moderate |
Methodological Recommendations
-
For epitope stability: Use differential scanning calorimetry (DSC) to assess T10B9-TCRαβ complex thermal stability .
-
In vivo validation: Employ A129 mouse models (as in SFTSV studies ) to test T10B9’s efficacy in composite tissue transplantation .
-
Resistance monitoring: Implement single-cell TCR sequencing pre/post therapy to track clonal T-cell dynamics.
